Compare, Analyse VENUS REMEDIES with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ADCOCK INGRAM
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ADCOCK INGRAM
Jun-14
VENUS REMEDIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs126349-   
Low Rs61252-   
Sales per share (Unadj.) Rs301.8103.7-  
Earnings per share (Unadj.) Rs-24.9-26.1-  
Cash flow per share (Unadj.) Rs2.5-21.7-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.381.4-  
Shares outstanding (eoy) m12.34168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 10.7%   
Avg P/E ratio x-3.8-11.5 32.7%  
P/CF ratio (eoy) x36.7-13.9 -265.2%  
Price / Book Value ratio x0.33.7 8.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,15450,658 2.3%   
No. of employees `0000.94.3 21.5%   
Total wages/salary Rs m3933,179 12.4%   
Avg. sales/employee Rs Th4,026.14,078.4 98.7%   
Avg. wages/employee Rs Th425.0740.6 57.4%   
Avg. net profit/employee Rs Th-331.8-1,027.7 32.3%   
INCOME DATA
Net Sales Rs m3,72417,508 21.3%  
Other income Rs m23123 18.4%   
Total revenues Rs m3,74717,631 21.3%   
Gross profit Rs m395-3,034 -13.0%  
Depreciation Rs m338756 44.8%   
Interest Rs m354474 74.7%   
Profit before tax Rs m-275-4,141 6.6%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32259 12.2%   
Profit after tax Rs m-307-4,412 7.0%  
Gross profit margin %10.6-17.3 -61.2%  
Effective tax rate %-11.5-6.2 183.7%   
Net profit margin %-8.2-25.2 32.7%  
BALANCE SHEET DATA
Current assets Rs m2,63812,823 20.6%   
Current liabilities Rs m2,3057,215 31.9%   
Net working cap to sales %8.932.0 27.9%  
Current ratio x1.11.8 64.4%  
Inventory Days Days135111 122.1%  
Debtors Days Days46124 37.4%  
Net fixed assets Rs m4,8717,475 65.2%   
Share capital Rs m12381 151.8%   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,61913,742 26.3%   
Long term debt Rs m1,3744,829 28.5%   
Total assets Rs m7,50925,960 28.9%  
Interest coverage x0.2-7.7 -2.9%   
Debt to equity ratio x0.40.4 108.1%  
Sales to assets ratio x0.50.7 73.5%   
Return on assets %0.6-15.2 -4.2%  
Return on equity %-8.5-32.1 26.4%  
Return on capital %1.6-19.8 -8.0%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m5141,494 34.4%  
From Investments Rs m-123-459 26.8%  
From Financial Activity Rs m-3874,383 -8.8%  
Net Cashflow Rs m45,418 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.81 Rs / ZAR

Compare VENUS REMEDIES With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: PROCTER & GAMBLE HEALTH  AUROBINDO PHARMA  WOCKHARDT  FRESENIUS KABI ONCO.  IPCA LABS  



Today's Market

Key Q2FY20 Results, BHEL Stake Sale, and Top Cues in Focus Today(Pre-Open)

On Friday, Indian share markets traded on a positive note most of the day and ended higher. The BSE Sensex logged total gains of 1,417 points in the past six sessions.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 18, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS